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Electrochemical affinity biosensors 
for fast detection of gene-specific 
methylations with no need 
for bisulfite and amplification 
treatments
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María Pedrero  1, Rodrigo Barderas2, Pablo San Segundo-Acosta2, Alberto Peláez-García3, 
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This paper describes two different electrochemical affinity biosensing approaches for the simple, fast 
and bisulfite and PCR-free quantification of 5-methylated cytosines (5-mC) in DNA using the anti-5-mC 
antibody as biorecognition element. One of the biosensing approaches used the anti-5-mC as capture 
bioreceptor and a sandwich type immunoassay, while the other one involved the use of a specific DNA 
probe and the anti-5-mC as a detector bioreceptor of the captured methylated DNA. Both strategies, 
named for simplicity in the text as immunosensor and DNA sensor, respectively, were implemented 
on the surface of magnetic microparticles and the transduction was accomplished by amperometry 
at screen-printed carbon electrodes by means of the hydrogen peroxide/hydroquinone system. The 
resulting amperometric biosensors demonstrated reproducibility throughout the entire protocol, 
sensitive determination with no need for using amplification strategies, and competitiveness with 
the conventional enzyme-linked immunosorbent assay methodology and the few electrochemical 
biosensors reported so far in terms of simplicity, sensitivity and assay time. The DNA sensor exhibited 
higher sensitivity and allowed the detection of the gene-specific methylations conversely to the 
immunosensor, which detected global DNA methylation. In addition, the DNA sensor demonstrated 
successful applicability for 1 h-analysis of specific methylation in two relevant tumor suppressor genes 
in spiked biological fluids and in genomic DNA extracted from human glioblastoma cells.
Growing cancer incidence and mortality worldwide demands the development of new reliable methodologies for 
the determination of specific cancer biomarkers useful for accurate diagnosis and prognosis of the disease as well 
as for patient monitoring1. It is well known that detection of malignant tumors at an early stage is the key to suc-
cessful treatment and outcome. Because molecular alterations in neoplastic cells may precede clinically obvious 
cancer, these changes have emerged as useful targets for such early detection. In addition to DNA sequence aber-
rations, like point mutations, deletions, rearrangements, or copy number variations, epigenetic modifications, 
such as DNA methylation, have proven to be an important parameter of neoplastic DNA. In fact, the detection 
and quantification of epigenetic modifications has become a powerful tool for the detection of both primary and 
metastatic or recurrent cancer cases and response to treatment2.
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Unlike genetic mutation, DNA methylation, identified as one of the most frequent molecular phenomenon 
in human cancers, is a heritable and reversible process that alters gene expression patterns without modifying 
the DNA sequence3,4. Both hypomethylation and hypermethylation states are associated with human cancer and 
affect different genome regions regarding the cancer type5. Hypomethylation, often detected in metastatic tissues 
and primary tumors increases the expression of oncogenes, activates transcription, and alters genome stability5,6. 
Hypermethylation of CpG-rich genomic regions occurs by altered activity of DNA methyltransferases (DNMTs) 
and involves the addition of a methyl group to the cytosine ring of those cytosines that precede a guanosine 
(referred to as CpG dinucleotides) to form 5-methylcytosine (5-mC). This process is considered an early event 
in the development of cancer3,7–9. Aberrant DNA methylation is frequently observed in tumor cells with global 
hypomethylation and hypermethylation of the CpG islands, which are clusters of CpGs, in the promoter regions 
of tumor suppressor genes. Indeed, inactivation of tumor suppressor genes, such as the RASSF1A and MGMT, 
via hypermethylation of CpG islands located in their regulatory regions, has been shown to be one of the most 
important mechanisms producing changes in their gene expression and leading to a number of human can-
cers4,6,10. Therefore, the detection of altered DNA methylation patterns in the promoter region of cancer related 
genes, in DNA derived both from tumor tissues and bodily fluids is considered to be a promising target for 
early diagnosis of cancers, tumor behavior monitoring, and response to targeted therapy or recognition of recur-
rence4,6,11,12. As a relevant datum to this respect, it was reported that aberrant methylation of the p16Ink4 and 
MGMT promoters can be detected in DNA from the sputum of patients with squamous cell carcinoma nearly 3 
years before clinical diagnosis13.
Common methods to detect DNA methylation include fluorescence-based polymerase chain reaction (PCR), 
sequencing and immuno/affinity reaction biosensing9. However, prior to DNA methylation detection using PCR 
and sequencing methods, DNA samples must be pre-treated either by restriction enzymes digestion or by bisulfite 
conversion2,11,14. During enzymatic digestion, methylation-sensitive restriction enzymes recognized and cleaved 
unmethylated CpG islands leaving intact the methylated CpG islands. Then the methylation status is assessed in 
connection with PCR using primers able to amplify only regions containing restriction sites15. Despite the useful-
ness for identifying highly methylated genes, this method is prone to false positive results due to incomplete enzy-
matic digestion of unmethylated CpG islands6,15. Bisulfite conversion changes only unmethylated cytosine bases 
to uracils via sulphonation, hydrolytic deamination, and alkali desulphonation16, and afterwards PCR amplifi-
cation using primers specific for methylated and unmethylated CpG islands is carried out15. While cytosines at 
unmethylated CpG islands are converted to uracils and bind adenines, methylated CpG islands resist conversion 
and consequently bind guanines during amplification15. However, as with the enzymatic digestion, incomplete 
bisulfite conversion sometimes causes false positive results. Various locus-based methods have been proposed to 
establish the methylation status of bisulfite-converted DNA, including methylation-specific PCR (MSP), quantita-
tive real-time MSP (qMSP), and pyrosequencing6,17. However, the use of specialized PCR equipment makes these 
approaches labor-intensive, time-consuming and quite expensive, thus limiting their use in general laboratories. 
On the other hand, there are several commercially available enzyme-linked immunosorbent assay (ELISA) kits 
which enable the quick assessment of global DNA methylation profiling using DNA amounts between 100 ng and 
2 μg. However, they are typically prone to high variability and, therefore, only suitable for the rough estimation 
of DNA methylation18.
Fluorescence, capillary electrophoresis19, colorimetry20, surface plasmon resonance21 and surface enhanced 
Raman spectroscopy22 have been also employed to detect specific DNA methylation pattern23. These method-
ologies, although effective, tend to be expensive, tedious and DNA and time-consuming for many applications.
In addition, the affinity of the methyl-binding protein (MBD)24,25 and the anti-methylcytosine antibody (anti-
5-mC)4,14 for 5-mC in a double stranded (ds)- or single stranded (ss)-target DNA sequence, respectively, has 
been exploited to construct a few biosensors for rapid monitoring of DNA methylation9,26. However, these bio-
sensors lack nucleic acid amplification, this constraining their sensitivity and applicability for the analysis of real 
specimens containing low amounts of methylated DNA. Thus, there is still an urgent demand to develop simple, 
inexpensive and rapid methods for high sensitive monitoring of DNA methylation11,27.
Electrochemical techniques have been widely used for sensitive and specific analysis of nucleic acids28,29 and 
also for DNA methylation assays because of their convenience, field portability, intrinsic simplicity, high selec-
tivity, high sensitivity and short analysis time4,7,23,30–32. Several PCR independent electrochemical methods for 
methylated DNA have been reported4,7,11,23,25,27,33–39. Although most of the electrochemical affinity biosensors 
reported so far comply with the required sensitivity4,24 using nanomaterials, the variability of the nanomaterials 
and their bio-functionalization often affect their reproducibility and quantification, especially for real samples11,40. 
Therefore, most of the electrochemical biosensors reported so far were mostly limited to the analysis of synthe-
sized DNA targets, and provided overall pictures of DNA methylation instead of information about distinct pat-
terns in DNA sequence27. In addition, their practice in clinical sample analysis has been only scarcely explored23.
In this work, aiming at improving the speed, simplicity, sensitivity and usefulness of the biosensors devel-
oped for monitoring of DNA methylation, two handy electrochemical biosensing strategies (an immunosensor 
and a DNA sensor) using neither bisulfite conversion nor nucleic acid amplification are reported to identify the 
methylation status of cytosine in DNA. The applicability of these strategies has been demonstrated by targeting 
the promoter methylation status of two normally non-methylated, biologically significant cancer genes, both in 
spiked biological fluids (RASSF1A), and genomic DNA extracted from human glioblastoma cells (MGMT).
Results
Two different electrochemical biosensing strategies for evaluating DNA methylation in a direct and independent 
PCR mode are described in this work. Specific promoter sequences of RASSF1A and MGMT genes were selected 
to verify the suitability of the designed strategies. The RAS association (RalGDS/AF-6) domain family member 
1A RASSF1A gene is a tumor suppressor gene frequently detected to undergo epigenetic silencing by aberrant 
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hypermethylation of its promoter region in many human solid tumors. It has been reported to have clinical sensi-
tivity of 67–75% for stage IV breast cancer2,41,42. On the other hand, methylation of the O6-methylguanine-DNA 
methyltransferase (MGMT) of the MGMT promoter of malignant glioma appears to be a useful predictor of the 
responsiveness to alkylating agents that reverse epigenetic alterations. Numerous studies have demonstrated that 
patients with silencing MGMT respond better to therapy13,43.
The first strategy (Fig. 1a) is an immunosensor involving the use of two different antibodies. The one immobilized 
on the surface of carboxylic acid-modified magnetic beads (HOOC-MBs), is specific to 5-methylcytosine (anti-5-mC) 
and, therefore, capable of capturing any ss-DNA sequence bearing this type of methylation. A second antibody conju-
gated with peroxidase (HRP-anti-ssDNA), able to recognize any ss-DNA, was used as detector antibody.
The second method (Fig. 1b) is a DNA sensor involving immobilization of a biotinylated DNA capture probe, 
specific to the methylated sequence to be detected, on the surface of Streptavidin-modified MBs (Strep-MBs). 
Methylation in the captured target DNA was recognized by means of the specific anti-5-mC tagged with a second-
ary HRP-conjugated antibody (HRP-anti-mouse IgG). In both strategies, amperometric determination was car-
ried out using the hydrogen peroxide/hydroquinone (H2O2/HQ) system after magnetic capture of the modified 
MBs on the surface of a screen-printed carbon electrode (SPCE), by measuring the cathodic current generated 
by the enzymatic reduction of H2O2 mediated by HQ, this current being proportional to the concentration of 
methylated DNA in the sample.
Optimization of the experimental conditions. Because methylation frequently is present in a little 
subset of cells in a clinical specimen, the sensitivity is critical to design an analytical method for monitoring the 
methylation status of the target gene11,44. Therefore, seeking for a high sensitivity and for simple and short assay 
protocols, the relevant experimental variables involved in the biosensors preparation were optimized. The taken 
selection criterion was the largest ratio between the current values measured at a potential value of −0.20 V (vs. 
the Ag pseudo-reference electrode) using the H2O2/HQ system, in the absence (B) and in the presence of 5.0 nM 
of synthetic target RASSF1A (S). The evaluated variables, the tested ranges and the values selected for further 
work are summarized in Table 1. Other experimental variables not included in the Table, such as the MBs sus-
pension volume45,46 and the potential applied for the amperometric response47 were optimized in previous works.
Illustrative examples of these optimization studies, such as the capture and detector antibodies loadings in the 
immunosensor and the biotinylated capture probe (bCp) concentration and number of steps for the DNA sensor, 
are displayed in Fig. 2a–d. Figure 2a and b show as the S/B ratio increased with the concentration of the capture 
and detector antibodies up to a certain concentration and then decreased significantly due to the sterically hin-
dered antigen binding when high loadings of antibodies are immobilized48. The somewhat higher signal obtained 
in the absence than in the presence of target methylated DNA without anti-5-mC (Fig. 2a) may be attributed to a 
slightly higher non-specific adsorption of HRP-anti-ssDNA on HOOC-MBs in this case.
Regarding the optimization of the bCp concentration in the DNA sensor (Fig. 2c), while no significant dif-
ferences were apparent between the B signals, the S signals increased significantly with the bCp concentration 
up to 0.1 μM, then decreasing for larger concentrations, which is most likely due to the restricted hybridization 
efficiency when large amounts of bCp are immobilized49,50. Results achieved in the optimization of all the other 
experimental variables are shown in Figure S1 (in the Supplementary Information).
Looking for a protocol simplification with reduced assay time, the influence of the number of steps used in 
the preparation of the DNA sensor was also investigated. All the evaluated protocols started after preparation of 
bCp-MBs and involved 30 min-incubation steps. The tested protocols consisted of: (a) incubation of bCp-MBs 
with a mixture solution containing the target DNA, the anti-5-mC and the HRP-anti-mouse IgG (1 step); (b) a 
former incubation with the target DNA solution and a second one with an anti-5-mC and the HRP-anti-mouse 
Figure 1. Schematic display of the biosensors’ fundamentals. Schematic display of the immunosensor (a) and 
the DNA sensor (b) developed for the determination of 5-mC methylation and the amperometric detection 
using the H2O2/HQ system at the SPCE.
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IgG mixture solution (2 steps); (c) independent and successive incubations with target DNA, anti-5-mC and 
HRP-anti-mouse IgG solutions (3 steps). Figure 2d shows as the working protocol involving two incubation steps 
provided the largest S/B current ratio. This protocol, additionally, allows reducing largely the total assay time. 
The observed results could be attributed to a less efficient hybridization of the target DNA labelled with both 
antibodies onto the bCp-MBs (1 step), and to a better recognition of the anti-5-mC by the HRP-anti-mouse IgG 
when both antibodies are free in solution. Consequently, a 2-step protocol involving the former hybridization 
of the target DNA onto the bCp-MBs and further labeling of the captured methylated DNA by incubation in an 
anti-5-mC and HRP-anti-mouse IgG mixture solution was selected for further work.
Analytical characteristics. The calibration plots and the analytical characteristics obtained with the two 
developed biosensing strategies for the methylated synthetic sequences of the promoter regions of the selected 
genes are displayed in Fig. 3 and summarized in Table 2. The limit of detection (LOD) values achieved allowed the 
Biosensor Variable Evaluated range Selected value
Immunosensor
[anti-5-mC], µg mL−1 0.4–10 4
anti-5-mC incubation time, min 15–90 60
HRP-anti-ssDNA dilution 1/50–1/500 1/100
HRP-anti-ssDNA incubation time, min 15–60 15
Target DNA incubation time, min 15–60 30
DNA sensor
[bCp], µM 0.01–0.5 0.1
bCp incubation time, min 15–60 15
Number of steps 1–3 2
Target DNA incubation time, min 15–60 30
[anti-5-mC], µg mL−1 0.25–2.0 0.5
[HRP-anti-mouse IgG], µg mL−1 0.125–2.0 1.0
anti-5-mC + HRP-anti-mouse IgG mixture incubation time, min 15–120 30
Table 1. Optimization of the experimental variables affecting the performance of the amperometric biosensors 
developed for quantification of DNA methylation.
Figure 2. Optimization of experimental variables. Influence of the capture (a) and detector (b) antibodies 
concentration used in the immunosensor fabrication, and the bCp concentration (c) and the number of steps 
(d) used in the preparation of the DNA sensor, on the amperometric responses measured with the developed 
biosensors for 0.0 (white bars) and 5.0 nM of synthetic target RASSF1A (grey bars) and the corresponding S/B 
ratio values (in red). Error bars estimated as triple of the standard deviation of three replicates. Data presented in 
(a–c) have been obtained using the optimal protocol described in MBs modification subsection involving 2 steps.
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detection of 0.3–1.0 fmol of methylated target gene’s promoter. The reproducibility of the amperometric responses 
obtained with different biosensors prepared in the same manner was evaluated by comparing the current values 
measured for 0.5 and 1.0 nM of synthetic target for the immuno- and DNA sensor, respectively. As it can be 
observed in Table 2, the relative standard deviation (RSD) values demonstrated great reproducibility in both 
biosensors preparation protocols as well as in the amperometric transduction.
When we compared the sensitivity achieved with the developed immunosensor with a commercial ELISA 
methodology for the same methylated DNA standard (E. coli genomic DNA with 346,670 methylated cytosines), 
we observed that the immunosensor provided a 2,500 times lower LOD (0.004 vs. 10 ng) in a 4-times shorter assay 
time (45 min vs. 3 h). Also, the LOD achieved with the immunosensor is 4.7-times lower (6.8 vs. 32 pM) than that 
reported for an electrochemical immunosensor for 5-hmC methylation (determination of 5-hydroxymethyl-2′
-deoxycytidine-5′-triphosphate)36.
It is important to remark that both developed methodologies allowed methylated DNA to be determined at 
picomolar level in about 1 h, with no need for bisulfite and amplification pretreatments and excellent reproduc-
ibility throughout the entire protocols. However, the DNA sensor exhibits better sensitivity (see comparative 
amperograms in (Fig. 3b). Moreover, the existence of 5 methylated cytosines in the part of the sequence that 
remains unhybridized (the only ones recognized by the anti-5-mC)14 in the synthetic target RASSF1A compared 
with the 4 in the MGMT, apart from the longest length of the hybrid fragment, explains the slightly higher sensi-
tivity achieved for the determination of the target RASSF1A.
Figure 3. Standards calibration plots. Calibration plots constructed with the immunosensor (a) and the DNA 
(b) biosensors for the methylated synthetic sequences of the promoter regions of RASSF1A ( ) and MGMT 
( ) genes. Amperometric responses obtained with the immunosensor (left) and the DNA sensor (right) in the 
absence and in the presence of 5.0 nM of the target RASSF1A. Error bars estimated as triple of the standard 
deviation of three replicates.
Parameter Immunosensor DNA sensor
Linear dependence ic vs. log [RASSF1A] ic vs. [RASSF1A] ic vs. [MGMT]
r 0.997 0.999 0.999
Slope (188 ± 3) nA (98 ± 1) × 104 nA µM−1 (84 ± 1) × 104 nA µM−1
Intercept, nA (1,077 ± 11) nA (710 ± 20) nA (390 ± 16) nA
Linear range, pM 23–24,000 139–5,000 87–2,500
LOD, pM 6.8 (0.3 fmol, 4.8 pg) 42 (1.0 fmol, 16.0 pg) 26 (0.6 fmol, 9.7 pg)
RSD, %* 3.9 (n = 10, 0.5 nM) 4.8 (n = 7, 1.0 nM) 4.3 (n = 7, 1.0 nM)
Assay time, min 45 60 60
Table 2. Analytical characteristics obtained with the biosensors developed for the determination of the 
synthetic methylated target DNA sequences of the promoter region of the RASSF1A and MGMT genes.  
*indicated in parentheses the concentration at which RSD has been calculated.
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Interestingly, a comparison between the electrochemical methods reported so far for the determination of 
different types of targets (synthetic oligonucleotides, free DNA bases, PCR products and genomic DNA), demon-
strates that the LODs achieved with the DNA sensor for the synthetic short target methylated DNAs are much 
lower than those reported with PCR amplification (25 pg)11, as well as for PCR-free methods using direct oxida-
tion of DNA bases of short methylated oligonucleotides (0.11 μM)35 and free un-methylated C (0.6 μM)38, diges-
tion by a restriction enzyme of a synthetic target DNA (10 nM)27, bisulfite conversion of synthetic target DNAs 
(18 pM)34 and PCR products (0.5 nM)37, and a paired-end tagging and amplification electrochemical strategy for 
methylated genomic DNA (40 pg)23. It is important to note also that the most sensitive strategies among these 
required assay times between 1.5 and 24.5 h11,23,34 compared to the 1 h of the DNA sensors developed in this work.
It is worth to mention also that although the LODs achieved with the developed biosensors are higher than 
those claimed for other two reported affinity electrochemical biosensors for synthetic target methylated DNAs 
determination, 2 fM4 and 35 fM24, the preparation of these biosensors required multiple reagents and complex 
and time-consuming working protocols that included amplification strategies involving nanomaterials. Moreover, 
in both cases the assay time is 3–5 times longer than that needed with the developed biosensors (2 h 40 min4 and 
4 h 50 min)24. It is important to highlight also that, apart from the shorter assay time and the inherent simplicity 
of the biosensors construction, these allow an accurate and straightforward determination of the synthetic target 
methylated DNA in spiked biological samples without previous extraction or amplification of the genetic mate-
rial, as it will be shown in further on.
In addition, the storage stability of the anti-5-mC-MBs and the bCp-MBs employed for the preparation of 
the immuno- and DNA sensors, respectively, was evaluated by storing the modified MBs at 4 °C in microcentri-
fuge tubes containing 50 μL of filtered phosphate-buffered saline (PBS) or Binding and Washing buffer (B&W), 
respectively. Subsequently, they were used to prepare biosensors on different working days and to measure the 
amperometric responses for 0.0 and 0.5 nM of target RASSF1A or 1.0 nM of target MGMT solutions, respectively. 
No significant decrease in the measured S/B ratio was observed during at least 35 days in both cases (no longer 
times were assayed), suggesting the possibility of preparing the conjugated MBs in advance and storing them 
under the above-described conditions, until the biosensor preparation is required.
Selectivity. The selectivity of both biosensors towards 5-mC was evaluated by comparing the amperometric 
responses they provided for 1.0 ng of denatured synthetic DNA standards containing unmodified cytosines (C), 
5-mC or 5-hmC. Results shown in Fig. 4 demonstrate the specificity of the developed methodologies to detect 
only 5-mC sequences. In addition, as predicted, the immunosensor detected the presence of any oligonucleotide 
with 5-mC methylation without any sequence selectivity. Accordingly, this sensor was able to quantify the total 
amount of 5-mCs in the analyzed DNA. Conversely, the DNA sensor only recognized the methylated sequence 
complementary to the bCp immobilized on the functionalized MBs and thus it can be used to simultaneously 
detect the presence of 5-mCs and their position in the DNA sequence.
Detection of 5-mC DNA methylation in biofluids and cells. The evaluation of the usefulness of the 
developed methodologies was restricted to the DNA sensor because of its higher sensitivity and suitability for 
quantification of gene-specific methylation as compared with the immunosensor. Such evaluation was accom-
plished in biological fluids supplemented with synthetic methylated target RASSF1A.
The comparison of the amperometric responses obtained with the DNA sensor in the absence and in the presence 
of 5.0 nM (125 fmol) of the synthetic target RASSF1A prepared in buffered solution and in the different biological fluids 
tested 25%-diluted with 5-mC-ELISA buffer is shown in (Fig. 5a). The slope values corresponding to calibration plots 
prepared between 139 and 5,000 pM of the synthetic target RASSF1A in each media are summarized in Table 3. The 
comparison of the obtained slope values revealed the existence of matrix effects in serum and urine samples and, there-
fore, in these biological samples the determination should be carried out by interpolation in the representative calibra-
tion plots constructed in the 25%-diluted biological fluids instead of the calibration constructed for synthetic target in 
buffer (case of saliva samples). The results obtained in the recovery studies performed in these biological samples spiked 
with 2.5 nM of the synthetic target RASSF1A for a confidence level of 0.95 (summarized in Table 3) outline the reliability 
of the approach to determine a low concentration of the synthetic target in biological fluids just after a simple dilution 
and without prior DNA extraction and preconcentration. These results are considered particularly relevant taking into 
account that the commercial ELISA methods, as well as most of the biosensors described so far for methylation deter-
mination, have proved to be suitable only for the analysis of previously extracted DNA, but not directly in biological 
samples, and after applying bisulfite and/or amplification treatments.
It is important to note that most of the work reported in the literature only provides semi-quantitative data 
or comparative percentages of methylation in healthy and cancer patients. Therefore, it is extremely difficult to 
find any reference indicating the absolute value of the methylated target DNA concentration in liquid biopsies 
samples. Some indication about the concentration of circulating hypermethylated RASSF1A in serum from breast 
cancer patients, between 1 and 200 ng mL−1, is given by Kristiansen et al.42, while the best cut-off for circulating 
serum RASSF1A to differentiate the hepatocellular carcinoma is 13 pM according to Mansour et al.51.
Despite the interesting results achieved in spiked serum, saliva and urine, it is important to mention that 
in most clinical applications DNA methylation detection at specific gene positions is much more relevant than 
quantification of DNA methylation. Therefore, in order to check the clinical applicability of the developed DNA 
sensor, the implemented methodology was applied to analyze the endogenous MGMT status in the reference 
cell line U87. Figure 5b shows that a larger amperometric response was measured when 100 ng genomic DNA 
extracted from these cells were analyzed, in comparison with the currents measured for both in the absence of 
target DNA and genomic DNA extracted from HeLa cells (non-methylated MGMT gene promoter cells used as 
control)52, which is consistent with the reported specific hypermethylation of the MGMT gene of U87 cell line53,54.
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All these results confirmed that the developed electrochemical DNA sensor exhibits suitable sensitivity and spec-
ificity for the determination in just 1 h of gene-specific methylations directly in biological fluids without previous 
DNA extraction and pretreatments (bisulfite and/or amplification), and in genomic DNA extracted from cells.
Discussion
This paper describes the development of two electrochemical biosensing strategies free of bisulfite and/or ampli-
fication pretreatments for the simple, sensitive and quick detection of DNA methylation using functionalized 
MBs, the anti-5-mC as affinity bioreceptor and amperometric detection at SPCEs using the H2O2/HQ system. 
Figure 4. Selectivity of biosensors. Comparison of the amperometric responses obtained with the 
inmunosensor (a) and the DNA sensor for RASSF1A promoter region (b) in the absence of DNA (blank) and in 
the presence of 1 ng of unmethylated and methylated with 5-mC and 5-hmC DNA standards and the synthetic 
methylated target DNA sequence of the RASSF1A and MGMT promoters region. Error bars estimated as triple 
of the standard deviation of three replicates.
Figure 5. Analysis of spiked biological samples. Comparison of the amperometric responses provided by the 
DNA sensor in the absence and in the presence of 5.0 nM of the synthetic target RASSF1A prepared in different 
media. Error bars estimated as triple of the standard deviation of three replicates (a). Amperometric responses 
measured with the DNA biosensor in the absence of synthetic target MGMT and in the presence of 100 ng of 
fragmented genomic DNA extracted from U87 cells and HeLa cells (b).
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While the immunosensor uses the anti-5-mC immobilized onto HOOC-MBs as capture bioreceptor, the DNA 
sensor employs the anti-5-mC as detector bioreceptor to label the methylated DNA previously captured by a com-
plementary DNA capture probe immobilized on the surface of Strep-MBs. Both sensors types imply simple and 
reproducible working protocols free of the complex and time consuming procedures required by the conventional 
methodologies. However, the DNA sensor exhibits a higher sensitivity and a clear discrimination only for the 
methylated sequence complementary to the immobilized capture probe. The obtained results demonstrated the 
suitability of the DNA sensor for detection of the gene-specific methylation without PCR amplification, bisulfite 
or labeling processes, directly in genomic DNA extracted from cells and in liquid biopsies without previous DNA 
extraction or amplification. In comparison with conventional ELISA available approaches, the developed sensors 
can greatly benefit research on DNA methylation in terms of convenience, low-cost, ease of operation and suit-
ability for universal analysis of any DNA sequence. These sensors offer also very interesting features over other 
electrochemical biosensors described to date in terms of sensitivity and assay time. Moreover, the fact that they 
do not require complicated nanomaterials preparation, conventional methylated DNA pretreatments or sophisti-
cated instruments for signal readout makes them economical and compatible with portable and low-cost devices 
to perform studies of DNA methylation-related functional genomics and epigenomics in different settings or at 
the point-of-need. These attractive capabilities can make these biosensing strategies to serve as a basis for devel-
oping easy and affordable tests in an easy-to-use format, not too technically demanding and requiring equipment 
readily available at most academic institutions for cancer suspects as well as for management and better outcome 
of cancer patients, complementing current and future pathological and molecular assessments.
Methods
Apparatus and electrodes. Amperometric measurements were performed with a CH Instruments (Austin, 
TX) model 812B potentiostat controlled by software CHI812B. SPCEs (DRP-110), consisting of a 4-mm diam-
eter carbon working electrode, a carbon counter electrode and an Ag pseudo-reference electrode were used as 
electrochemical transducers, and the specific cable connector (DRP-CAC), which acted as interface between the 
SPCEs and the potentiostat, were purchased from DropSens (Spain). All the electrochemical measurements were 
performed at room temperature. A neodymium magnet (AIMAN GZ) embedded in a homemade Teflon casing 
was used for the reproducible magnetic capture of the modified-MBs on the surface of SPCEs.
A Bunsen AGT-9 Vortex for homogenization of the solutions, a Raypa steam sterilizer, a biological safety 
cabinet Telstar Biostar, a thermocycler (SensoQuest LabCycler, Progen Scientific Ltd.), an incubator shaker 
Optic Ivymen® System (Comecta S. A, Sharlab) and a magnetic particle concentrator DynaMag™-2 (123.21D, 
Invitrogen Dynal AS) were also employed.
Reagents and Solutions. All reagents used were of the highest available analytical grade. Strep-MBs (2.8 µm 
Ø, 10 mg mL−1, Dynabeads M-280 Streptavidin, 11206D) and HOOC-MBs (2.7 μm Ø, 10 mg mL−1, Dynabeads 
M-270 carboxylic acid, Cat. No: 14305D) were purchased from Thermo Fisher Scientific. NaCl, KCl, NaH2PO4, 
Na2HPO4 and Tris–HCl were purchased from Scharlab. 2-(N-morpholino)ethanesulfonic acid (MES) was pur-
chased from Gerbu. N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDC), N-hydroxysulfosuccinimide 
(sulfo-NHS) were purchased from Fluorochem. Ethanolamine, HQ and H2O2 (30%, w/v) were purchased from 
Sigma-Aldrich.
Mouse anti-5-methylcytosine monoclonal antibody (anti-5-mC), anti-DNA antibody conjugated with HRP 
(HRP-anti-ssDNA) and 897 bp linear dsDNA standards containing 201 cytosines either unmodified (C DNA 
standard), 5-methylcytosine (5-mC DNA standard) or 5-hydroxymethylcytosine (5-hmC DNA standard) from 
DNA Standard Set (Cat. No. D5405) were purchased from Zymo Research. An HRP-labeled anti-mouse IgG from 
Abcam was also used.
Human sera from clotted whole blood (in lyophilized powder) were purchased from Sigma-Aldrich. Saliva 
and urine samples were collected from healthy volunteers. A Salivette® collection device (Sarstedt) was used for 
collecting the saliva samples. Fragmented HeLa genomic DNA used as control in the cells experiments was a 
component of the EpiMark Methylated DNA Enrichment Kit (New England Biolabs, Inc.).
The following buffer solutions, prepared with Milli-Q water (18 MΩ cm at 25 °C) and sterilized after their 
preparation, were used: PBS consisting of 0.01 M phosphate buffer solution containing 137 mM NaCl and 2.7 mM 
KCl, pH 7.5, 0.1 M Tris–HCl, pH 7.2, 0.1 M phosphate buffer, pH 8.0; 0.025 M MES buffer, pH 5.0, B&W buffer 
consisting of 10 mM Tris–HCl solution containing 1 mM EDTA and 2 M NaCl, pH 7.5, Tris–EDTA buffer (TE) 
consisting of 0.01 M Tris–HCl solution containing 1 mM EDTA, pH 8.0 and 0.05 M phosphate buffer, pH 6.0. 
Commercial 5-mC ELISA Buffer (Cat. No.: D5325-2-250) and 10 × ELISA Buffer (Cat. No.: D5425-2-30) from 
Zymo Research were also used.
Medium Slope, nA µM−1 Recovery(n=3), %
Buffer (98 ± 1) × 104 101 ± 4
Serum 25% (76 ± 7) × 104 97 ± 5
Saliva 25% (98 ± 14) × 104 95 ± 6
Urine 25% (72 ± 6) × 104 94 ± 7
Table 3. Slope values obtained with the DNA sensor for the calibration plots obtained for synthetic target 
RASSF1A prepared in buffer and in different biological samples and results obtained in the recovery studies 
performed with the developed DNA sensor in samples spiked with 2.5 nM of the synthetic target RASSF1A.
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All DNA synthetic oligonucleotides used were purchased from Integrated DNA Technologies and their 
sequences are summarized in Table 4. All of them were reconstituted upon reception in TE buffer to a final con-
centration of 100 μM, divided into small aliquots and stored at −80 °C.
It is worth to mention at this point that the probe and target methylated DNA strands were designed according 
to the specific promoter sequence of RASSF1A4 and MGMT55 genes, and that methylated and unmethylated target 
DNAs have similar hybridization capacity to probe oligonucleotides27.
MBs modification. MBs modification was different depending on the type of biosensor prepared (Fig. 1). 
The following protocols were used:
•	 Immunosensor (Fig. 1a): A 3-μL aliquot of the HOOC-MBs commercial suspension was placed into a 1.5 mL 
Eppendorf tube and washed twice with 50 μL of MES buffer for 10 min (25 °C, 950 rpm). Thereafter, carboxyl 
groups of the magnetic microcarriers were activated by incubation in 25 μL of a freshly EDC/sulfo-NHS solu-
tion (50 mg mL−1 each, in MES buffer, pH 5.0) for 35 min (25 °C, 950 rpm) and, after two washing steps with 
MES buffer, the microbeads were incubated in 100 μL of an anti-5-mC solution (4 µg mL−1 in 0.025 M MES 
buffer, pH 5.0) for 60 min (37 °C, 950 rpm). Subsequently, the anti-5-mC-MBs were washed twice with 50 μL 
of MES buffer (0.025 M, pH 5.0) and incubated with 25 μL of 1 M ethanolamine solution (prepared in 0.1 M 
phosphate buffer, pH 8.0) for 60 min (25 °C, 950 rpm). After this blocking step, three washings were carried 
out with 50 µL Tris–HCl (0.1 M, pH 7.2), the first one, and with 1 × ELISA buffer (prepared by dilution from 
the 10 × ELISA buffer), the following two. Subsequently, the anti-5-mC-MBs were incubated with 48 μL of 
the target DNA solution (RASSF1A) for 30 min (37 °C, 950 rpm). Two washings were performed with 50 μL 
1 × ELISA buffer and the target DNA/anti-5-mC-MBs were incubated with 25 μL of an HRP-anti-ssDNA 
solution (dil. 1/100 in 1 × ELISA buffer) for 15 min (25 °C, 950 rpm). Finally, two washings were carried out 
with 50 μL of 1 × ELISA buffer and the modified particles were re-suspended in 50 μL of phosphate buffer 
solution (0.05 M, pH 6.0) to carry out the amperometric measurement.
•	 DNA sensor (Fig. 1b): 5 μL of the Strep-MBs commercial suspension were deposited in a 1.5 mL Eppendorf 
tube. After performing two washing steps with 50 µL of B&W buffer solution (pH 7.5), the Strep-MBs were 
re-suspended and incubated for 15 min (37 °C, 950 rpm) in 25 µL of 0.1 µM of the corresponding b-DNACp 
solution (bCp-RASSF1A or bCp-MGMT) prepared in B&W (pH 7.5). Thereafter, the b-DNACp-MBs were 
washed twice with 50 μL of 5-mC-ELISA buffer and incubated in 25 µL of the synthetic target DNA (RASSF1A 
or MGMT) solution (prepared in 5-mC-ELISA buffer) for 30 min (37 °C, 950 rpm). Subsequently, two addi-
tional washings were carried out with 50 µL of the 5-mC-ELISA buffer, and the target/b-DNACp-MBs 
were incubated for 30 min (37 °C, 950 rpm) with 100 μL of an anti-5-mC (0.5 μg mL−1) and anti-IgG-HRP 
(1.0 μg mL−1) mixture solution in 5-mC-ELISA buffer. After two final washings with 50 μL of 5-mC-ELISA 
buffer, the modified particles were resuspended in 50 µL of phosphate buffer solution (0.05 M, pH 6.0) to 
perform the amperometric detection.
Amperometric detection. In both types of sensors, the modified MBs were magnetically and reproduc-
ibly captured on the working carbon electrode surface by pipetting 50 μL of the modified MBs suspension onto 
the SPCE upon allocating it on a homemade Teflon casing with an encapsulated neodymium magnet. Then, the 
SPCE/magnet holding block ensemble was immersed into an electrochemical cell containing 10 mL of 0.05 M 
phosphate buffer of pH 6.0 and 1.0 mM HQ (prepared just before performing the electrochemical measurement). 
Amperometric measurements in stirred solutions were made at −0.20 V vs. Ag pseudo-reference electrode. Once 
the background current was stabilized, 50 μL of a 0.1 M H2O2 solution were added and the generated current 
recorded until the steady-state current was reached (∼100 s). The amperometric measurements given through 
the whole manuscript corresponded to the difference between the steady-state and the background currents and 
are the average of at least three replicates (confidence intervals calculated for α = 0.05). The LOD values were 
estimated according to the 3 × sb/m criteria, sb being the standard deviation (n = 10) for measurements made in 
the absence of target DNA and m the slope value of the corresponding calibration plot.
Analysis in cells and spiked biological fluids. The applicability of the developed methodology in bio-
logical fluids was evaluated by comparing the sensitivity achieved in buffered solutions with those obtained in 
biological samples (human saliva, serum and urine) spiked with increasing concentrations of the methylated 
synthetic sequence of the RASSF1A promoter region and performing recovery studies in these complex matrices.





Table 4. Oligonucleotides used in this work. C(M): 5-methylcytosine (5-mC). *The positions of biotin in both 
Cps were selected to place the high number of 5-mCs in the synthetic targets farther away from the surface of 
MBs to make there more accessible for anti-5-mC recognition.
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In addition, U87 cells were grown at 37 °C in a humidified atmosphere containing 5% CO2 and maintained in 
high-glucose DMEM (Dulbecco’s modified Eagle’s medium), supplemented with fetal bovine serum (10%), penicil-
lin (100 U mL−1), streptomycin (100 μg mL−1), and L-glutamine (2.5 mM) (GIBCO-Invitrogen, Carlsbad, CA, USA).
Genomic DNA was isolated from these cells with QIAamp DNA FFPE Tissue Kit (Valencia, CA, USA) accord-
ing to the manufacturer’s instructions with minor modifications. DNA concentrations and quality were measured 
using a Nanodrop 1000A spectrophotometer (Wilmington, DE, USA), obtaining ratio values confirming pure 
DNA in all cases. Due to DNA from tissue biopsies is fragmented when isolated from FFPE, genomic DNA from 
U87 was sonicated 3 cycles of 10 s at 30% amplitude for fragmentation.
The analysis of genomic DNA extracted from cells and the 897 bp linear dsDNA standards involved their previous 
denaturation by heating at 97 °C for 5 min in a thermocycler and transferring immediately to ice for 10 min just before 
making the determination with the biosensor using a similar protocol to that followed with the synthetic target DNAs.
This study and all the experimental protocols used were performed according to the guidelines and regu-
lations and approved by the University Complutense of Madrid. It is worth to mention that since the samples 
analyzed were commercial serum samples and urine and saliva collected from one of the authors of this paper (V. 
Ruiz-Valdepeñas Montiel) no other written informed consents were required.
References
 1. Costa-Pinheiro, P., Montezuma, D., Henrique, R. & Jerónimo, C. Diagnostic and prognostic epigenetic biomarkers in cancer. 
Epigenomics 7, 1003–1015 (2015).
 2. Ahmed, I. A. et al. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma 
detected in extracellular tumor DNA. Cancer Genet. Cytogenet. 199, 96–100 (2010).
 3. Chiam, K., Ricciardelli, C. & Bianco-Miotto, T. Epigenetic biomarkers in prostate cancer: Current and future uses. Cancer Lett. 342, 
248–256 (2014).
 4. Daneshpour, M., Syedmoradi, L., Izadi, P. & Omidfar, K. Femtomolar level detection of RASSF1A tumor suppressor gene 
methylation by electrochemical nano-genosensor based on Fe3O4/TMC/Au nanocomposite and PT-modified electrode. Biosens. 
Bioelectron. 77, 1095–1103 (2016).
 5. Ehrlich, M. DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400–5413 (2002).
 6. Cheuk, I. W. Y., Shin, V. Y. & Kwong, A. Detection of methylated circulating DNA as noninvasive biomarkers for breast cancer 
diagnosis. J. Breast Cancer 20, 12–19 (2017).
 7. Wang, G. L., Zhou, L. Y., Luo, H. Q. & Li, N. B. Electrochemical strategy for sensing DNA methylation and DNA methyltransferase 
activity. Anal. Chim. Acta 768, 76–81 (2013).
 8. Furst, A. L., Muren, N. B., Hill, M. G. & Barton, J. K. Label-free electrochemical detection of human methyltransferase from tumors. 
PNAS 111, 14985–14989 (2014).
 9. Krejcova, L., Richtera, L., Hynek, D., Labuda, J. & Adam, V. Current trends in electrochemical sensing and biosensing of DNA 
methylation. Biosens. Bioelectron. 97, 384–399 (2017).
 10. Gao, L. et al. Methylated APC and RASSF1A in multiple specimens contribute to the differential diagnosis of patients with 
undetermined solitary pulmonary nodules. J. Thorac. Dis. 7, 422–432 (2015).
 11. Liu, S., Zhang, X. & Zhao, K. Methylation-specific electrochemical biosensing strategy for highly sensitive and quantitative analysis 
of promoter methylation of tumor-suppressor gene in real sample. J. Electroanal. Chem. 773, 63–68 (2016).
 12. Calapre, L., Warburton, L., Milward, M., Ziman, M. & Gray, E. S. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. 
Cancer Lett. 404, 62–69 (2017).
 13. Bhatt, A. N., Mathur, R., Farooque, A., Verma, A. & Dwarakanath, B. S. Cancer biomarkers-Current perspectives. Indian J. Med. Res. 
132, 129–149 (2010).
 14. Kurita, R. & Niwa, O. DNA Methylation analysis triggered by bulge specific immuno-recognition. Anal. Chem. 84, 7533–7538 (2012).
 15. Herman, J. G., Graff, J. R., Myöhänen, S., Nelkin, B. D. & Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation 
status of CpG islands. Proc. Natl. Acad. Sci. USA 93, 9821–9826 (1996).
 16. Clark, S. J., Statham, A., Stirzaker, C., Molloy, P. L. & Frommer, M. DNA methylation: bisulphite modification and analysis. Nat. 
Protoc. 1, 2353–2264 (2006).
 17. Laird, P. W. Principles and challenges of genome wide DNA methylation analysis. Nat. Rev. Genet. 11, 191–203 (2011).
 18. Kurdyukov, S. & Bullock, M. DNA methylation analysis: choosing the right method. Biology 5, 3, https://doi.org/10.3390/
biology5010003 (2016).
 19. Su, F. et al. Highly sensitive and multiplexed analysis of CpG methylation at single-base resolution with ligation-based exponential 
amplification. Chem. Sci. 6, 1866–1872 (2015).
 20. Geng, Y., Wu, J., Shao, L., Yan, F. & Ju, H. Sensitive colorimetric biosensing for methylation analysis of p16/CDKN2 promoter with 
hyperbranched rolling circle amplification. Biosens. Bioelectron. 61, 593–597 (2014).
 21. Sina, A. A. et al. Methylsorb: A simple method for quantifying DNA methylation using DNA–gold affinity interactions. Anal. Chem. 
86, 10179–10185 (2014).
 22. Hu, J. & Zhang, C. Single base extension reaction-based surface enhanced Raman spectroscopy for DNA methylation assay. Biosens. 
Bioelectron. 31, 451–457 (2012).
 23. Chen, F., Wang, X., Cao, X. & Zhao, Y. Accurate electrochemistry analysis of circulating methylated DNA from clinical plasma based 
on paired-end tagging and amplifications. Anal. Chem. 89, 10468–10473 (2017).
 24. Yin, H. et al. A new strategy for methylated DNA detection based on photoelectrochemical immunosensor using Bi2S3 nanorods, 
methyl bonding domain protein and anti-histag antibody. Biosens. Bioelectron. 51, 103–108 (2014).
 25. Wee, E. J. H., Ngo, T. H. & Trau, M. Colorimetric detection of both total genomic and loci-specific DNA methylation from limited 
DNA inputs. Clin. Epigenet. 7, 65, https://doi.org/10.1186/s13148-015-0100-6 (2015).
 26. Kurita, R. & Niwa, O. Microfluidic platforms for DNA methylation analysis. Lab Chip 16, 3631–3644 (2016).
 27. Dai, Z., Hu, X., Wu, H. & Zou, X. A label-free electrochemical assay for quantification of gene-specific methylation in a nucleic acid 
sequence. Chem. Commun. 48, 1769–1771 (2012).
 28. Paleček, E. & Bartošík, M. Electrochemistry of nucleic acids. Chem. Rev. 112, 3427–3481 (2012).
 29. Ferapontova, E. E. Basic concepts and recent advances in electrochemical analysis of nucleic acids. Curr. Opin. Electrochem. 5, 
218–225 (2017).
 30. Taleat, Z., Mathwig, K., Sudholter, E. J. R. & Rassaei, L. Detection strategies for methylated and hypermethylated DNA. TrAC, Trends 
Anal. Chem. 66, 80–89 (2015).
 31. Gao, F. et al. Highly efficient electrochemical sensing platform for sensitive detection DNA methylation, and methyltransferase 
activity based on Ag NPs decorated carbon nanocubes. Biosens. Bioelectron. 99, 201–208 (2018).
 32. Campuzano, S. & Pingarrón, J. M. Electrochemical sensing of cancer-related global and locus-specific DNA methylation events. 
Electroanalysis, https://doi.org/10.1002/elan.201800004 in press.
www.nature.com/scientificreports/
1 1SCIENTIFIC REPoRTs |  (2018) 8:6418  | DOI:10.1038/s41598-018-24902-1
 33. Kato, D. et al. Electrochemical DNA methylation detection for enzymatically digested CpG oligonucleotides. Anal. Chem. 83, 
7595–7599 (2011).
 34. Wang, P., Wu, H., Dai, Z. & Zou, X. Picomolar level profiling of the methylation status of the p53 tumor suppressor gene by a label-
free electrochemical biosensor. Chem. Commun. 48, 10754–10756 (2012).
 35. Wang, P., Hana, P., Dong, L. & Miao, X. Direct potential resolution and simultaneous detection of cytosine and 5-methylcytosine 
based on the construction of polypyrrole functionalized graphene nanowall interface. Electrochem. Commun. 61, 36–39 (2015).
 36. Yang, Z. et al. A novel electrochemical immunosensor for the quantitative detection of 5-hydroxymethylcytosine in genomic DNA 
of breast cancer tissue. Chem. Commun. 51, 14671–14673 (2015).
 37. Yanagisawa, H., Kurita, R., Yoshida, T., Kamata, T. & Niwa, O. Electrochemical assessment of local cytosine methylation in genomic 
DNA on a nanocarbon film electrode fabricated by unbalanced magnetron sputtering. Sens. Actuator B-Chem. 221, 816–822 (2015).
 38. Wang, L., Yu, F., Wang, F. & Chen, Z. Electrochemical detection of DNA methylation using a glassy carbon electrode modified with 
a composite made from carbon nanotubes and β-cyclodextrin. J. Solid State Electrochem. 20, 1263–1270 (2016).
 39. Haraguchi, K. et al. Oral cancer screening based on methylation frequency detection in hTERT gene using electrochemical 
hybridization assay via a multi-electrode chip coupled with ferrocenylnaphthalene diimide. Electroanalysis 29, 1596–1601 (2017).
 40. Zhang, H. Q., Zhao, Q., Li, X. F. & Le, X. C. Ultrasensitive assays for proteins. Analyst 132, 724–737 (2007).
 41. Kristiansen, S., Jørgensen, L. M., Hansen, M. H., Nielsen, D. & Sölétormos, G. Concordance of hypermethylated DNA and the tumor 
markers CA 15–3, CEA, and TPA in serum during monitoring of patients with advanced breast cancer. BioMed Res. Int. Volume 
2015, Article ID 986024, 6 pages, https://doi.org/10.1155/2015/986024 (2015).
 42. Kristiansen, S., Nielsen, D. & Sölétormos, G. Detection and monitoring of hypermethylated RASSF1A in serum from patients with 
metastatic breast cancer. Clin. Epigenet. 8, 35, https://doi.org/10.1186/s13148-016-0199-0 (2016).
 43. Switzeny, O. J. et al. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting 
high-grade glioma response. Clin. Epigenet. 8, 49, https://doi.org/10.1186/s13148-016-0204-7 (2016).
 44. Suijkerbuijk, K. P. M., Pan, X., Wall, E., Diest, P. J. & Vooijs, M. Comparison of different promoter methylation assays in breast 
cancer. Anal. Cell. Pathol. 33, 133–141 (2010).
 45. Pedrero, M. et al. Disposable amperometric immunosensor for the determination of human p53 protein in cell lysates using 
magnetic micro-carriers. Biosensors 6, 56, https://doi.org/10.3390/bios6040056 (2016).
 46. Vargas, E. et al. Magnetic beads-based sensor with tailored sensitivity for rapid and single-step amperometric determination of 
miRNAs. Int. J. Mol. Sci. 18, 2151, https://doi.org/10.3390/ijms18112151 (2017).
 47. Conzuelo, F., Gamella, M., Campuzano, S., Reviejo, A. J. & Pingarrón, J. M. Disposable amperometric magneto-immunosensor for 
direct detection of tetracyclines antibiotics residues in milk. Anal. Chim. Acta 737, 29–36 (2012).
 48. Eletxigerra, U. et al. Estrogen receptor α determination in serum, cell lysates and breast cancer cells using an amperometric 
magnetoimmunosensing platform. Sens. Biosensing Res. 7, 71–76 (2016).
 49. Liu, S. F. et al. Enzyme-free and label-free ultrasensitive electrochemical detection of DNA and adenosine triphosphate by dendritic 
DNA concatamer-based signal amplification. Biosens. Bioelectron. 56, 12–18 (2014).
 50. Zouari, M., Campuzano, S., Pingarrón, J. M. & Raouafi, N. Competitive RNA-RNA hybridization-based integrated 
nanostructureddisposable electrode for highly sensitive determination of miRNAs in cancer cells. Biosens. Bioelectron. 91, 40–45 (2017).
 51. Mansour, L. A. et al. Circulating hypermethylated RASSF1A as a molecular biomarker for diagnosis of hepatocellular carcinoma. 
Asian Pac. J. Cancer Prev. 18(6), 1637–1643 (2017).
 52. Ishiguro, K. et al. Expression of O6-methylguanine-DNA methyltransferase examined by alkyl-transfer assays, methylation-specific 
PCR and Western Blots in tumors and matched normal tissue. J. Cancer Ther. 4(4), 919–931 (2013).
 53. Caldera, V. et al. MGMT hypermethylation and MDR system in glioblastoma cancer stem cells. Cancer Genom. Proteom. 9, 171–178 
(2012).
 54. Yi, G.-Z. et al. Akt and β-catenin contribute to TMZ resistance and EMT of MGMT negative malignant glioma cell line. J. Neurol. 
Sci. 367, 101–106 (2016).
 55. Thon, N., Kreth, S. & Kreth, F.-W. Personalized treatment strategies in glioblastoma: MGMT promoter methylation status. 
OncoTargets Ther. 6, 1363–1372 (2013).
Acknowledgements
The financial support of the Spanish Ministerio de Economía y Competitividad CTQ2015-64402-C2-1-R and 
SAF2014-53209-R Research Projects, the PI17CIII/00045 research project from AESI and the NANOAVANSENS 
Program from the Comunidad de Madrid (S2013/MT-3029) and predoctoral contracts from the Spanish 
Ministerio de Economía y Competitividad (R.M. Torrente-Rodríguez and E. Povedano) and Universidad 
Complutense de Madrid (V. Ruiz-Valdepeñas Montiel) are also gratefully acknowledged.
Author Contributions
M.P., R.B., A.P.-G., M.M., D.H., S.C. and J.M.P. conceived and designed the experiments. E.P., E.V., V.R.-V.M., 
R.M.T.-R and P.S.S.-A. performed the experiments. S.C. and J.M.P. analyzed the data and wrote the paper. All 
authors discussed and commented on the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-24902-1.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
